ArticleThe American journal of gastroenterology2017
Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Cyclic Vomiting Syndrome in Children.Frontiers in neurology · 2020Pooled it
- Endocannabinoid signaling in stress, nausea, and vomiting.Neurogastroenterology and motility · 2025Review
- Cyclic vomiting syndrome: Future clinical and research priorities for: Special supplement/proceedings of 3rd international symposium.Neurogastroenterology and motility · 2025Review
- Landscape of Cyclic Vomiting Syndrome: From Bedside to Bench, Past to Present.Neurogastroenterology and motility · 2025Review
- Acute and Long-Term Effects of App-Delivered Heartfulness Meditation on Psychological Outcomes and the Endocannabinoid Signaling System in Cyclic Vomiting Syndrome.Clinical and translational gastroenterology · 2024Article
- Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure.Frontiers in toxicology · 2024Review
- Whole exome/genome sequencing in cyclic vomiting syndrome reveals multiple candidate genes, suggesting a model of elevated intracellular cations and mitochondrial dysfunction.Frontiers in neurology · 2023Article
- [Clinical and gastroscopic features of children with cyclic vomiting syndrome: an analysis of 63 cases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.Cannabis and cannabinoid research · 2022Article
- The childhood migraine syndrome.Nature reviews. Neurology · 2021Review
- Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in gastroparesis: A sex- and subtype-dependent observation.Neurogastroenterology and motility · 2021Article
- Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.Cannabis and cannabinoid research · 2020Review
- Association of a Variant ofFrontiers in genetics · 2020Article
- Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions.Neurogastroenterology and motility · 2019Review
- Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?Journal of Crohn's & colitis · 2019Review
- Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders.Current treatment options in gastroenterology · 2018Review
- Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans.Neurogastroenterology and motility · 2018Review
- Cyclic vomiting syndrome: epidemiology, diagnosis, and treatment.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018Review
- Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCyclic vomiting syndrome (CVS) is a disorder defined by recurrent, unexplained episodes of severe nausea and vomiting. Our aim was to investigate whether CVS and pathophysiological mechanisms underlying this condition are associated with selected variations in genes encoding the components of the endogenous cannabinoid and opioid systems.
methodsThis case-control study included 65 patients with CVS-16 male and 49 female, and 1,092 healthy controls-525 male and 567 female from the 1000 Genomes Project. CVS subjects filled out study-specific questionnaires. Single-nucleotide polymorphisms (SNPs) in genes encoding cannabinoid receptors (CNR1 and CNR2), fatty acid amide hydrolase (FAAH) and mu-opioid receptor (OPRM1) were analyzed using the TaqMan SNP genotyping assay. Correlations between SNP's and clinical characteristics of CVS were ascertained.
resultsOur study disclosed an increased risk of CVS among individuals with AG and GG genotypes of CNR1 rs806380 (P<0.01), whereas the CC genotype of CNR1 rs806368 and AG and GG genotypes of OPRM1 rs1799971 were associated with a decreased risk of CVS (P<0.05). In addition, AG and GG genotypes of OPRM1 rs1799971 were correlated with migraine episodes, AG and GG of OPRM1 rs1799971, and CT and CC of CNR1 rs806368 with a family history of migraines (second degree relatives), and CT and CC of CNR1 rs2023239 with a positive response to therapy.
conclusionsOur results show for the first time that the variations in CNR1 and OPRM1 genes are associated with CVS and that different genotypes may contribute to the risk of CVS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.